Prometic Life Sciences Inc operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-450-7810115
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$39.91 million
Profitability
Miscellaneous
Employees487
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
ProMetic Life Sciences (TSE:PLI) Frequently Asked Questions
What is ProMetic Life Sciences' stock symbol?
ProMetic Life Sciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "PLI."
How were ProMetic Life Sciences' earnings last quarter?
ProMetic Life Sciences Inc. (TSE:PLI) issued its quarterly earnings results on Monday, August, 12th. The company reported ($2.51) earnings per share (EPS) for the quarter. The firm earned $8.75 million during the quarter. View ProMetic Life Sciences' Earnings History.
When is ProMetic Life Sciences' next earnings date?
What price target have analysts set for PLI?
4 Wall Street analysts have issued 12 month price objectives for ProMetic Life Sciences' stock. Their forecasts range from C$0.30 to C$0.70. On average, they expect ProMetic Life Sciences' share price to reach C$0.43 in the next twelve months. This suggests that the stock has a possible downside of 96.8%. View Analyst Price Targets for ProMetic Life Sciences.
What is the consensus analysts' recommendation for ProMetic Life Sciences?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProMetic Life Sciences in the last year. There are currently 1 sell rating and 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ProMetic Life Sciences.
Has ProMetic Life Sciences been receiving favorable news coverage?
Press coverage about PLI stock has trended somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. ProMetic Life Sciences earned a news impact score of -1.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for ProMetic Life Sciences.
Who are some of ProMetic Life Sciences' key competitors?
Some companies that are related to ProMetic Life Sciences include Concordia International (CXR), Mesoblast (MSB), Kodiak Sciences (KOD), BELLUS Health (BLU), Paradigm Biopharmaceuticals (PAR), Biotest (BIO), Neptune Wellness Solutions (NEPT), Aprea Therapeutics (APRE), Starpharma (SPL), Oxford BioMedica (OXB), TELIX Pharmaceutical (TLX), Bellus Health (BLU), Theratechnologies (TH), Rafael (RFL) and Resverlogix (RVX).
What other stocks do shareholders of ProMetic Life Sciences own?
Based on aggregate information from My MarketBeat watchlists, some companies that other ProMetic Life Sciences investors own include Nemaska Lithium (NMX), ProMetic Life Sciences (PFSCF), Bombardier, Inc. Class B (BBD.B), Crescent Point Energy (CPG), Sierra Wireless (SWIR), Baytex Energy (BTE), Aurora Cannabis (ACB), Dollarama (DOL), Parkland Fuel (PKI) and Canopy Growth (CGC).
Who are ProMetic Life Sciences' key executives?
ProMetic Life Sciences' management team includes the folowing people:
- Mr. Kenneth H. Galbraith, CEO & Director (Age 56)
- Mr. Bruce Pritchard, International COO & Interim CFO
- Mr. Patrick Sartore, Chief Legal Officer & Corp. Sec.
- Mr. Bruce Wendel, Chief Bus. Devel. Officer (Age 65)
- Dr. John Moran, Chief Medical Officer (Age 73)
How do I buy shares of ProMetic Life Sciences?
Shares of PLI and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is ProMetic Life Sciences' stock price today?
One share of PLI stock can currently be purchased for approximately C$13.54.
How big of a company is ProMetic Life Sciences?
What is ProMetic Life Sciences' official website?
How can I contact ProMetic Life Sciences?
ProMetic Life Sciences' mailing address is 440 Armand-Frappier Blvd Suite 300, LAVAL, QC H7V 4B4, Canada. The company can be reached via phone at +1-450-7810115.
MarketBeat Community Rating for ProMetic Life Sciences (TSE PLI)
MarketBeat's community ratings are surveys of what our community members think about ProMetic Life Sciences and other stocks. Vote "Outperform" if you believe PLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
